Oral Wegovy insurance coverage has expanded significantly in 2026, driven by the cardiovascular benefit data from the SELECT trial[1] and the new Medicare anti-obesity drug coverage provision. Approximately 40% to 50% of commercial insurance plans now cover oral Wegovy for weight management, up from roughly 25% in 2024. Medicare Part D began covering it for qualifying beneficiaries in 2026. Here is how to find coverage for your specific situation.
Key Takeaways
- About 40-50% of commercial insurance plans cover oral Wegovy in 2026, with significant variation by plan.
- Medicare Part D now covers anti-obesity medications including oral Wegovy under specific criteria (new 2026).
- Prior authorization is required by nearly all insurers and typically takes 2-7 business days.
- If denied, appeal success rates range from 30% to 50% with proper documentation.
- The Novo Nordisk savings card can reduce copays to $0-$25 for commercially insured patients.
Overview: the Insurance space in 2026
Coverage for weight loss medications has been one of the fastest-changing areas in health insurance over the past three years. Several factors have driven this shift: For a complete cost breakdown, see our cheapest semaglutide options.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
- SELECT trial results (2023): The demonstration that semaglutide reduces major cardiovascular events by 20% changed how insurers view the cost-benefit equation.
- Medicare expansion (2026): Congress authorized Medicare Part D coverage for anti-obesity medications, signaling a policy shift that private insurers are following.
- Employer demand: Large employers have pushed insurers to add GLP-1 coverage, recognizing that obesity treatment reduces downstream costs for diabetes, heart disease, and disability.
- AMA recognition: The American Medical Association's classification of obesity as a chronic disease has strengthened the medical necessity argument for coverage.
Coverage by Insurance Type
Commercial Insurance (Employer-Sponsored and Individual Plans)
| Coverage Status | % of Plans (Estimated) | Typical Copay |
|---|---|---|
| Covered, preferred formulary | 15-20% | $25-$75/month |
| Covered, non-preferred (higher tier) | 20-30% | $150-$500/month |
| Covered with prior authorization only | 10-15% | $50-$300/month (after PA approval) |
| Not covered (explicit exclusion) | 35-55% | Full retail price ($1,300-$1,500) |
The most important step is checking your specific plan. The same insurer (e.g., UnitedHealthcare, Aetna, Blue Cross) may cover oral Wegovy on one employer's plan and exclude it on another. Plan design matters more than the insurer's name. Contact provider for current pricing
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Medicare Part D
The Inflation Reduction Act amendments and subsequent legislation authorized Medicare Part D to cover anti-obesity medications beginning in 2026. Key criteria for Medicare coverage of oral Wegovy:
- BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity
- Documentation of failed lifestyle intervention (diet and exercise)
- Prescription from a physician (not just an NP or PA, depending on the plan)
- Prior authorization required in most Part D plans
- Estimated copay: $35 to $200 per month depending on the plan's benefit structure
This is a major development. Before 2026, Medicare explicitly excluded anti-obesity medications, leaving over 60 million beneficiaries without coverage.
Medicaid
Medicaid coverage for oral Wegovy varies dramatically by state. As of early 2026:
- Approximately 15 states cover some anti-obesity medications under Medicaid
- Coverage often requires prior authorization and step therapy (trying cheaper medications first)
- Many states still exclude weight loss drugs from their Medicaid formularies
Check your state's Medicaid formulary or ask your provider to verify coverage before starting treatment.
Tricare (Military)
Tricare has covered Wegovy since 2024 for beneficiaries meeting BMI criteria with documented comorbidities. Oral Wegovy is expected to receive the same coverage classification. Copays through Tricare are typically $25 to $75 per month.
How to Get Prior Authorization
Nearly every insurance plan that covers oral Wegovy requires prior authorization (PA). This is a process where your provider submits documentation proving medical necessity. Here is how it works:
What You Need
- Current BMI documentation (from a recent visit or self-reported weight and height verified by provider)
- List of weight-related comorbidities (hypertension, diabetes, sleep apnea, etc.)
- Documentation of previous weight loss attempts (diet, exercise, previous medications)
- Lab work showing metabolic markers (HbA1c, lipid panel, blood pressure readings)
- Provider's letter of medical necessity
The PA Timeline
| Step | Timeline | Who Does It |
|---|---|---|
| Provider submits PA request | Day 1 | Your prescribing provider's office |
| Insurance reviews request | Days 2-5 | Insurance company pharmacy team |
| Decision communicated | Days 3-7 | Insurance notifies provider |
| Prescription filled (if approved) | Days 4-10 | Pharmacy processes and ships |
At FormBlends, our team handles the entire PA process. We submit the necessary documentation, follow up with the insurer, and notify you of the outcome. This is included in our program, not an extra cost.
What to Do If You Are Denied
A denial isn't the end of the road. Here are your options:
1. Appeal the Decision
You have the right to appeal any insurance denial. Success rates for weight loss medication appeals range from 30% to 50% when supported by strong documentation.
Effective appeal strategies:
- Include detailed medical records showing BMI history and comorbidities
- Reference the SELECT trial cardiovascular data as evidence of medical benefit
- Document previous failed attempts at lifestyle modification and other medications
- Have your provider write a personal letter explaining why this medication is medically necessary for your specific case
- If applicable, cite the AMA's classification of obesity as a chronic disease
2. Request a Peer-to-Peer Review
Your provider can request a direct conversation with the insurance company's medical director. This peer-to-peer review allows your physician to make the case for medical necessity directly. These conversations overturn denials in approximately 30% to 40% of cases.
3. Ask About Step Therapy Alternatives
Some insurers deny oral Wegovy because they require you to try cheaper medications first (step therapy). If your plan requires step therapy, you may need to document a trial of phentermine, Contrave, or another medication before oral Wegovy is approved. Some plans accept a brief trial (4 to 8 weeks) as sufficient.
4. Check If Injectable Wegovy Is Covered Instead
Insurance coverage often differs between oral and injectable forms. If your plan covers injectable Wegovy but not the oral form (or vice versa), switching formulations is a practical solution. The weight loss results are equivalent. oral Wegovy vs alternatives
Savings Programs and Discount Options
| Program | Eligibility | Savings |
|---|---|---|
| Novo Nordisk Savings Card | Commercially insured patients (not Medicare/Medicaid) | Copay reduced to $0-$25/month |
| Novo Nordisk Patient Assistance Program | Uninsured patients below 400% FPL | Free medication |
| HSA/FSA | Any patient with these accounts | Pay with pre-tax dollars (20-35% effective savings) |
| Pharmacy discount programs (GoodRx, etc.) | Any patient | Limited savings on brand GLP-1 drugs |
Contact provider for current pricing
Comparisons: Coverage Across Weight Loss Medications
| Medication | % of Commercial Plans Covering | Medicare Part D | Typical Copay (Insured) |
|---|---|---|---|
| Oral Wegovy | 40-50% | Yes (new 2026) | $25-$300 |
| Injectable Wegovy | 45-55% | Yes (new 2026) | $25-$300 |
| Zepbound | 35-45% | Yes (new 2026) | $25-$300 |
| Ozempic | 70-80% | Yes (diabetes indication) | $25-$150 |
| Rybelsus | 65-75% | Yes (diabetes indication) | $25-$150 |
| Contrave | 40-50% | Varies | $30-$100 |
| Phentermine (generic) | 70-80% | Varies | $5-$20 |
Getting Started: Verifying Your Coverage
- Check your formulary. Log into your insurance portal or call the number on your insurance card. Ask specifically whether "oral semaglutide for weight management" or "oral Wegovy" is covered. Get the tier level and copay amount.
- Ask about prior authorization. Find out what documentation is required and whether step therapy applies.
- Consult with FormBlends. Our team can run a benefits verification on your behalf, identifying your copay, PA requirements, and any coverage gaps before you commit to treatment.
- Apply for the savings card. If you have commercial insurance, apply at the Novo Nordisk website before filling your first prescription. This can save hundreds per month.
- Explore alternatives if needed. If coverage is denied and appeals fail, we will help you find a covered or affordable alternative.
Frequently Asked Questions
Does my insurance have to cover oral Wegovy?
No. There's no federal or state mandate requiring private insurers to cover weight loss medications, even with the AMA's obesity disease classification. Medicare Part D now covers it, but individual commercial plans retain the right to exclude anti-obesity drugs. Coverage is a benefit design decision made by each plan.
Why does insurance cover Ozempic but not oral Wegovy?
Ozempic is approved for type 2 diabetes, and insurers are required to cover diabetes medications. Oral Wegovy is approved for weight management, which many plans still classify as an optional benefit. If you have type 2 diabetes, your provider may be able to prescribe Ozempic or Rybelsus (lower-dose oral semaglutide) under the diabetes indication.
Will Medicare cover oral Wegovy in 2026?
Yes. The 2026 Medicare Part D expansion includes coverage for FDA-approved anti-obesity medications. Prior authorization and specific eligibility criteria (BMI thresholds, documented comorbidities) apply. Contact your Part D plan for details.
Can I use my HSA or FSA to pay for oral Wegovy?
Yes. When prescribed for a medical condition (obesity), oral Wegovy is an eligible HSA/FSA expense. This effectively reduces your cost by your marginal tax rate (typically 20% to 35%).
What if my employer's plan doesn't cover weight loss drugs?
Ask your HR department to advocate for adding anti-obesity medication coverage during the next plan renewal. Employers are increasingly recognizing that covering weight loss treatment reduces long-term costs for diabetes, cardiovascular disease, and disability claims. You can also pay out of pocket or use compounded alternatives.
Is the Novo Nordisk savings card available for uninsured patients?
No. The savings card is only for patients with commercial insurance. Uninsured patients should apply for the Novo Nordisk Patient Assistance Program (PAP), which provides free medication to eligible low-income patients. Contact provider for current pricing
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Let Us Check Your Coverage
Finding insurance for oral Wegovy doesn't have to be stressful. FormBlends verifies your benefits, handles prior authorization, and helps you access the lowest possible price. Schedule your consultation today and we will determine your real cost before you start. get started